Prelude Therapeutics
PRLD
61 hedge funds and large institutions have $1.12B invested in Prelude Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 5 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
27.54% more ownership
Funds ownership: 73.38% → 100.92% (+28%)
14% more capital invested
Capital invested by funds: $986M → $1.12B (+$138M)
7% more funds holding
Funds holding: 57 → 61 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$20.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.3M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$6.39M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$6.33M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$3.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.53M |
| 2 |
Citigroup
New York
|
-$1.66M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$991K |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$648K |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$439K |
PRLD Hedge Fund Activity: Q3 2021 in Review
61 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2021, worth a combined $1.12B — up 14% from $986M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PRLD positions and 5 closed out — a net gain of 4 holders — while 25 added to existing stakes and 13 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $20.2M. The largest seller was State Street, cutting an estimated $6.53M.
- 61 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2021, up from 57 in Q2 2021.
- Funds reported $1.12B of Prelude Therapeutics stock for Q3 2021, up 14% quarter-over-quarter.
- 9 funds opened new Prelude Therapeutics positions in Q3 2021 and 5 closed out, a net change of +4 holders.
- The largest Prelude Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $20.2M added.
- The largest Prelude Therapeutics seller in Q3 2021 was State Street, an estimated $6.53M sold.
Based on aggregated 13F filings for Q3 2021.